Mipomersen
Orphan Drug Cold Chain RequiredFDA Approved
Description
Mipomersen is an antisense oligonucleotide inhibitor of apolipoprotein B-100 synthesis. It is indicated as an adjunct to lipid-lowering medications and diet to reduce LDL-C, apo B, total cholesterol, and non-HDL-C in patients with homozygous familial hypercholesterolemia (HoFH).
Indications & Therapeutic Use
Homozygous familial hypercholesterolemia
Linked Diseases:
Global Availability (1 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Mipomersen
| Generic Name | Mipomersen |
| Brands | 1 brand available |
| Active Ingredient | Mipomersen sodium |
| Drug Class | Homozygous familial hypercholesterolemia |
| Manufacturer | Ionis Pharmaceuticals |
| Dosage Forms | Subcutaneous injection, 200 mg/mL |
| Medical Code | C10AX13 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Required |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT00470875 |
| Countries | 1 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations2 Validated Nodes